(Q44204800)

30 November 2017

title

Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease (English)

1 reference

30 November 2017

1 reference

2

Tore K Kvien

1 reference

30 November 2017

Anne Grete Semb

1

1 reference

30 November 2017

David A DeMicco

3

1 reference

30 November 2017

Rana Fayyad

4

1 reference

30 November 2017

Chuan-Chuan Wun

5

1 reference

30 November 2017

John C LaRosa

6

1 reference

30 November 2017

John Betteridge

7

1 reference

30 November 2017

Terje R Pedersen

8

1 reference

30 November 2017

Ingar Holme

9

1 reference

30 November 2017

language of work or name

1 reference

1 September 2012

1 reference

30 November 2017

published in

Arthritis & Rheumatology

1 reference

30 November 2017

volume

64

1 reference

30 November 2017

issue

9

1 reference

30 November 2017

page(s)

2836-2846

1 reference

Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis

30 November 2017

cites work

1 reference

Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis.

21 January 2018

1 reference

Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study.

21 January 2018

1 reference

Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis.

21 January 2018

1 reference

Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis

21 January 2018

1 reference

Signs of accelerated preclinical atherosclerosis in patients with ankylosing spondylitis

21 January 2018

1 reference

Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis

21 January 2018

1 reference

Spondyloarthropathies: an independent cardiovascular risk factor?

21 January 2018

1 reference

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials

21 January 2018

1 reference

Efficacy of statins in familial hypercholesterolaemia: a long term cohort study

21 January 2018

1 reference

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

21 January 2018

1 reference

Towards improving cardiovascular risk management in patients with rheumatoid arthritis: the need for accurate risk assessment

21 January 2018

1 reference

Intensive lipid lowering in patients with rheumatoid arthritis and previous myocardial infarction: an explorative analysis from the incremental decrease in endpoints through aggressive lipid lowering (IDEAL) trial

21 January 2018

1 reference

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

21 January 2018

1 reference

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

21 January 2018

1 reference

Atherosclerosis — An Inflammatory Disease

21 January 2018

1 reference

Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction

21 January 2018

1 reference

The immune response in atherosclerosis: a double-edged sword

21 January 2018

1 reference

Immunopathology of psoriasis and psoriatic arthritis

21 January 2018

1 reference

Proinflammatory cytokines in heart disease

21 January 2018

1 reference

Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis

21 January 2018

1 reference

Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound.

21 January 2018

1 reference

Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) Study

21 January 2018

1 reference

Lipoproteins and their subfractions in psoriatic arthritis: identification of an atherogenic profile with active joint disease

21 January 2018

1 reference

Increased disease activity is associated with a deteriorated lipid profile in patients with ankylosing spondylitis

21 January 2018

1 reference

Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions

21 January 2018

1 reference

Overproduced interleukin 6 decreases blood lipid levels via upregulation of very-low-density lipoprotein receptor.

21 January 2018

1 reference

Effects of tumor necrosis factor blockade on cardiovascular risk factors in psoriatic arthritis: A double-blind, placebo-controlled study

21 January 2018

1 reference

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

A long-term, open-label trial of the safety and efficacy of etanercept (Enbrel) in patients with rheumatoid arthritis not treated with other disease-modifying antirheumatic drugs

21 January 2018

1 reference

Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis

21 January 2018

1 reference

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial

21 January 2018

1 reference

Statin therapy might be beneficial for patients with ankylosing spondylitis

21 January 2018

1 reference

Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.34524

1 reference

30 November 2017

1 reference